Hyloris to Report its Full Year 2020 Results on 9 March 2021
Liège, Belgium – 03 March 2021 – Hyloris Pharmaceuticals SA (Euronext Brussels: HYL), a specialty biopharma company committed to bringing new medicines that offer added value to underserved patient populations, today announces that it will publish its consolidated results for the year ended 31st December 2020 on Tuesday, 9 March 2021 at 7am CET.
The Company will host a conference call and webcast, conducted in English, to present the results, followed by a live Q&A session.
The webcast will be held on 9 March 2021 at 3pm CET / 2pm GMT / 9am EST. To join the webcast, please click here.
If you would like to join via a phone line, then please register via the above link and dial-in details will be sent to the email address you have used to register. For details or for help joining the webcast or conference call line, please contact Consilium Strategic Communications at hyloris@consilium-comms.com.
For more information, please contact:
Hyloris Pharmaceuticals
Marieke Vermeersch
VP Investor Relations and Corporate Communications
M: +32 (0)479 490 603
marieke.vermeersch@hyloris.com
Consilium Strategic Communications
Amber Fennell, Chris Welsh, Lucy Featherstone
T: +44 20 3709 5700
hyloris@consilium-comms.com
About Hyloris Pharmaceuticals
Hyloris is a specialty biopharma company identifying and unlocking hidden potential in existing medications for the benefit of patients and the healthcare system. Hyloris applies its knowhow and technological innovations to existing pharmaceuticals and has built a broad proprietary product pipeline that has the potential to offer significant advantages over currently available alternatives. Hyloris currently has two, partnered commercial-stage products, Sotalol IV for the treatment of atrial fibrillation, and Maxigesic® IV, a non-opioid analgesic for the treatment of pain. The Company’s development strategy primarily focuses on the FDA’s 505(b)2 regulatory pathway, which is specifically designed for pharmaceuticals for which safety and efficacy of the molecule has already been established. This pathway can reduce the clinical burden required to bring a product to market, and significantly shorten the development timelines and reduce costs and risks. Hyloris is based in Liège, Belgium. For more information, visit www.hyloris.com.
Disclaimer and forward-looking statements
Hyloris stands for “high yield, lower risk” and relates to the 505(b)(2) regulatory pathway for product approval on which the Issuer focuses, but in no way relates or applies to an investment in the Shares.
Certain statements in this press release are “forward-looking statements.” These forward-looking statements can be identified using forward-looking terminology, including the words "believes", "estimates," "anticipates", "expects", "intends", "may", "will", "plans", "continue", "ongoing", "potential", "predict", "project", "target", "seek" or "should", and include statements the Company makes concerning the intended results of its strategy. These statements relate to future events or the Company’s future financial performance and involve known and unknown risks, uncertainties, and other factors, many of which are beyond the Company’s control, that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements. The Company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.
Attachment
